Atossa Therapeutics, Inc. (ATOS) stock
ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.96+0.02 (+1.03%)
Close on Nov 13, 2026Market cap $19.56MP/E –Yield –
Atossa Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Atossa Therapeutics's ebitda for the twelve months ending Sep 30, 2023 was -$30.49M. For fiscal 2022 it was -$27.68M. The highest annual figure on record is -$3.41M in fiscal 2011.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$27.68M | – |
| FY2021 | Dec 31, 2021 | -$20.50M | – |
| FY2020 | Dec 31, 2020 | -$14.56M | – |
| FY2019 | Dec 31, 2019 | -$17.21M | – |
| FY2018 | Dec 31, 2018 | -$11.39M | – |
| FY2017 | Dec 31, 2017 | -$7.52M | – |
| FY2016 | Dec 31, 2016 | -$7.67M | – |
| FY2015 | Dec 31, 2015 | -$12.49M | – |
| FY2014 | Dec 31, 2014 | -$11.69M | – |
| FY2013 | Dec 31, 2013 | -$10.31M | – |
| FY2012 | Dec 31, 2012 | -$4.94M | – |
| FY2011 | Dec 31, 2011 | -$3.41M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | -$7.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.10M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.15M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.92M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.60M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.29M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.27M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.05M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.09M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.30M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.13M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.87M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.97M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.03M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.86M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.66M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.45M | – |
See a number that looks wrong?